Biotechnology

Fueled by a $100M R&D investment, Chinese beauty giant Yatsen is leading a market shift from price wars to scientific innovation, winning global consumers.

Taimei Technology and C&R Research forge a strategic alliance, deploying advanced AI to automate and accelerate drug development in Asia's key research hub.

Diathrive Health and AliveCor's KardiaComplete partner to offer an integrated solution for diabetes and heart disease, combating fragmented care and rising costs.

With a new marketing VP and patented light therapy, medical tech firm Revian is making a strategic play to dominate the booming at-home hair care industry.

A new obesity drug shows 19.3% weight loss with remarkably few side effects, while also improving blood pressure, cholesterol, and even bone density.

From a one-room office to a regional logistics leader, Excel Courier marks four decades of driving critical industries like healthcare and tech.

ABEC's expanded group integrates advanced modeling and custom engineering to accelerate drug development, reduce risk, and boost manufacturing efficiency.

The architect of HUMIRA's launch and Horizon's $28B sale is now shaping the next wave of drug companies from within private equity. What does it mean?

With a promising cancer pipeline, Crescent Biopharma heads to key May conferences to prove its strategy against fierce competition in the bispecific and ADC markets.

As EyePoint's losses widen to fund its lead drug, DURAVYU, the company is on the cusp of pivotal trial results that could redefine retinal disease treatment.

Preclinical data for CITY-RBP4 shows promise in treating Stargardt disease, a leading cause of juvenile blindness with no approved therapies.

A new global partnership aims to solve key bottlenecks in regenerative medicine by providing standardized, high-quality umbilical cord stem cells to researchers.

Empire Genomics & Molecular Instruments launch NISH, a fully automated system promising faster, clearer RNA-ISH results by preserving precious tissue samples.

Medical tech giant Convatec unveils a new arsenal of advanced wound care solutions, using nitric oxide and placental tech to combat hard-to-heal injuries.

The Aesthetic Syndicate evolves into Manor, launching a national brand that fuses injectables with medically supervised GLP-1 therapy and holistic health.

As FDA rules on peptides shift, a new AI platform aims to give doctors clarity, separating solid science from speculation in the booming longevity market.

Creatv Bio will present data at ASCO 2026 on its LifeTracDx® blood test, showcasing its potential to personalize cancer treatment through key pharma partnerships.

With six new collaborations, the life science leader aims to tame data complexity and accelerate discovery by creating a single, integrated software ecosystem.

A new partnership aims to solve banking woes for the multi-billion-dollar peptide and IV therapy industries, long deemed 'too risky' by traditional finance.

With a novel 'NewCo' model and key partnerships, Banyan BioInnovations aims to de-risk and accelerate clinical-stage drugs past the funding valley of death.